Dysis Medical Ltd, an Edinburgh, Scotland, UK-based developer of a colposcope used in cervical cancer screening, completed an £18m ($25m) funding round.
Lundbeckfonden Ventures made the investment.
The company is using the funds to continue expansion in the US, UK and other key territories, in addition to advancing strategic R&D programs.
Led by CEO Alastair Atkinson, DYSIS provides the DYSIS colposcope uses patented optical and software techniques to scan a patient’s cervix, quantify the results and present them to a clinician in the form of an intuitive colour-coded map (DYSISmap).
Within the past year, the company launched the latest generation device (DYSIS Ultra), published updated guidance recommending the adoption of Dysis by the NHS, and the US clinical data.
Dysis has its Headquarters in Edinburgh, UK and US offices in Tampa, FL.